Analyst Downgraded Stocks on the NAS May 2025

May 29, 2025

Analyst Downgrades

Companies are downgraded when at least one analyst has downgraded their view on the stock, therefore decreasing its average consensus value. Companies can get downgraded for a number of reasons but primarily due to reduced future earnings potential due to loss of contracts, faltering product lines, increasing costs relative to revenue or financial risk.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

About the Data

This table includes the number of analyst ratings along with the number of buy-hold-sells on the company. A company is included in this list when its mean rating decreases from the previous week.

How do you use this table?

Companies that have recently been downgraded are viewed as having potential future losses. Use this table as a starting point for further research on these companies. Stocks with analyst coverage also tend to have higher visibility in the marketplace, therefore have the potential to be more liquid. Stocks in this category are generally sold to preserve capital or held as a short position.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameBuyOutperformHoldUnderperformSellNo OpinionMean RatingPrev Mean LabelMean Label
ADBE Adobe Inc 6 1 3 0 0 0 4.3 4.4 Outperform
TEAM Atlassian Corp 4 0 3 0 0 0 4.1 4.3 Outperform
VIGL Vigil Neuroscience Inc 0 0 1 0 0 0 3.0 5.0 Hold
PRTA Prothena Corp PLC 1 0 2 0 0 0 3.7 4.3 Outperform
SCLX Scilex Holding Co 0 0 1 0 0 0 3.0 4.0 Hold
UBX Unity Biotechnology Inc 0 0 1 0 0 0 3.0 5.0 Hold
All data provided as at market close May 26, 2025.

Company Details

Adobe Inc

ADBE:NAS

Buy

6

Hold

3

Mean Rating

4.3

Prev Mean Rating

4.4

Mean Label

Outperform

Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).

Access the stockcalc valuation


Atlassian Corp

TEAM:NAS

Buy

4

Hold

3

Mean Rating

4.1

Prev Mean Rating

4.3

Mean Label

Outperform

Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions.

Access the stockcalc valuation


Vigil Neuroscience Inc

VIGL:NAS

Hold

1

Mean Rating

3.0

Prev Mean Rating

5.0

Mean Label

Hold

Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease.

Access the stockcalc valuation


Prothena Corp PLC

PRTA:NAS

Buy

1

Hold

2

Mean Rating

3.7

Prev Mean Rating

4.3

Mean Label

Outperform

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Scilex Holding Co

SCLX:NAS

Hold

1

Mean Rating

3.0

Prev Mean Rating

4.0

Mean Label

Hold

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain.

Access the stockcalc valuation


Unity Biotechnology Inc

UBX:NAS

Hold

1

Mean Rating

3.0

Prev Mean Rating

5.0

Mean Label

Hold

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Analysts downgraded Adobe and Atlassian on the NAS this month. See the full list of analyst downgrades on the blog: https://www.stockcalc.com/Blog/analyst-downgraded-stocks-nas-may-2025
Adobe $ADBE and Atlassian $TEAM downgraded on the #NAS this month. See the full list of downgrades: https://www.stockcalc.com/Blog/analyst-downgraded-stocks-nas-may-2025
Analysts downgraded Adobe and Atlassian on the NAS this month. See the full list of analyst downgrades on the blog: https://www.stockcalc.com/Blog/analyst-downgraded-stocks-nas-may-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.